Non-Small Cell Lung Cancer

Latest News

Advances in Oncology: When Innovation and Challenge Intersect
Advances in Oncology: When Innovation and Challenge Intersect

August 21st 2025

Precision oncology's promise was the key theme of the July 17 session of the Institute for Value-Based Medicine with faculty from multiple institutions in the Boston, Massachusetts area.

For Better Cancer Outcomes, It’s All About Access
For Better Cancer Outcomes, It’s All About Access

August 21st 2025

The Future of Oncology Is Driving Value, Access, Innovation From Inpatient to Outpatient Care
The Future of Oncology Is Driving Value, Access, Innovation From Inpatient to Outpatient Care

August 21st 2025

Lung cancer | Image credit: steph photographies - stock.adobe.com
Salvage Surgery a Possible Approach in NSCLC After Immunotherapy

August 15th 2025

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com
Predictive Model Forecasts Advanced NSCLC Outcomes

August 14th 2025

Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes

Get insight to advances in ALK+ NSCLC treatment, including long-term lorlatinib data, new therapy approvals, brain metastasis management, and evolving sequencing strategies with this series.

AJMC Peer Exchange logo
Continuing Medical Education
View All
August 26th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 26th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Joshua K. Sabari, MD, NYU Langone
September 30th 2024

Amivantamab Presents an Exciting Treatment Opportunity in NSCLC

Maggie L. Shaw
In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals from the FDA for use in non–small cell lung cancer (NSCLC).
Martin Dietrich, MD, PhD, Cancer Care Centers of Brevard
September 27th 2024

Amivantamab Accolades Add Up for NSCLC

Maggie L. Shaw
On September 19, the FDA handed down its third amivantamab (Rybrevant; Johnson & Johnson) approval for 2024 in non–small cell lung cancer (NSCLC), giving the third-generation tyrosine kinase inhibitor its fourth approval overall.
FDA | Image Credit: © wladimir1804-stockk.adobe.com
September 26th 2024

FDA Approves Osimertinib in Stage III NSCLC

Maggie L. Shaw
The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable stage III non–small cell lung cancer (NSCLC) with EGFR mutation.
AI generated lungs and doctor | Image credit: PRASANNAPIX - stock.adobe.com
September 20th 2024

FDA Approves Amivantamab for EGFR-Positive NSCLC With Exon 19 Deletion, Exon 21 L858R Substitution

Skylar Jeremias
The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut disease progression risk for EGFR-positive non–small cell lung cancer (NSCLC).
David P. Carbone, MD, PhD, The Ohio State University
September 16th 2024

Liquid Biopsy Advances: Vital Role in Biomarker Testing in Lung Cancer

Maggie L. Shaw
Here we conclude our discussion with David P. Carbone, MD, PhD, The Ohio State University, by addressing the importance of both advocacy for and education on biomarker testing in the lung cancer space.
Sparkling telomere | Image Credit: Dr_Microbe - stock.adobe.com
September 13th 2024

THIO Combo Yields Survival Benefit in Advanced NSCLC

Russ Conroy
Developers anticipate releasing full efficacy results from the phase 2 THIO-101 trial later this year.
Ana Baramidze, MD, PhD
September 9th 2024

EMPOWER-Lung 1 Trial Data Showcase Promise of Cemiplimab in NSCLC

Kyle Munz
Ana Baramidze, MD, PhD, Todua Clinic, Tbilisi, Georgia, details exciting findings from the EMPOWER-Lung 1 trial regarding cemiplimab and patients with non–small cell lung cancer (NSCLC).
Ticiana Leal, MD, Emory Winship Cancer Institute
September 5th 2024

Dr Ticiana Leal on Recent Advancements in Perioperative NSCLC Care

Rose McNulty
Ticiana Leal, MD, associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the latest advances in perioperative non–small cell lung cancer (NSCLC) treatment.
Joshua K. Sabari, MD, NYU Langone
August 30th 2024

Novel Mechanisms Set FDA-Approved Amivantamab-Lazertinib Combo Apart in NSCLC

Maggie L. Shaw
This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody.
Lung cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com
August 27th 2024

Measuring the Magnitude of Systemic Inflammatory Response in NSCLC

Julia Bonavitacola
Measures of systemic inflammation used for the liver, including C-reactive protein-albumin ratio and modified Glasgow prognostic score, demonstrated prognostic value in non–small cell lung cancer (NSCLC).
David P. Carbone, MD, PhD, The Ohio State University
August 23rd 2024

Beyond Early Stage: Biomarker Testing's Role in Advanced Lung Cancer

Maggie L. Shaw
In part 1 of our interview with David P. Carbone, MD, PhD, The Ohio State University, he addressed why it is important to conduct biomarker testing in both lung cancer overall and non–small cell lung cancer more specifically.
FDA Approved
August 20th 2024

Lazertinib With Amivantamab Approved by FDA for Use in NSCLC

Julia Bonavitacola
Patients with non-small cell lung cancer (NSCLC) can use lazertinib in combination with amivantamab as a first-line treatment.
A panel of 4 experts on lung cancer
August 19th 2024

Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Mark Socinski, MD John Heymach, MD, PhD Wade Iams, MD Sandip P. Patel, MD
The panel provides insights on enhancing outcomes for patients with metastatic non-small cell lung cancer without targetable driver mutations.
brain and lungs | Image Credit: magicmine-stock.adobe.com
August 15th 2024

ICIs Extend Survival in Older Patients With NSCLC, Brain Metastases

Maggie L. Shaw
This investigation was conducted among older, frail patients, a population typically underrepresented in clinical trials.
A panel of 4 experts on lung cancer
August 12th 2024

Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches

Mark Socinski, MD John Heymach, MD, PhD Wade Iams, MD Sandip P. Patel, MD
The panel shares clinical practices for overcoming immunotherapy resistance in patients with non-small cell lung cancer.
A panel of 4 experts on lung cancer
August 12th 2024

Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection

Mark Socinski, MD John Heymach, MD, PhD Wade Iams, MD Sandip P. Patel, MD
A panel of experts on non-small cell lung cancer outline factors that impact how well patients respond to immunotherapy.
Biomarker Testing: Key to Personalized Lung Cancer Care
August 9th 2024

Biomarker Testing: Key to Personalized Lung Cancer Care

Maggie L. Shaw
David P. Carbone, MD, PhD, director of the thoracic oncology center at The Ohio State University in Columbus, discusses the importance of biomarker testing in both lung cancer overall and non–small cell lung cancer specifically.
Lung cancer | Image credit: appledesign - stock.adobe.com
August 5th 2024

Study Suggests Need for New Second-Line NSCLC Therapies to Follow Osimertinib

Julia Bonavitacola
New therapies to treat EGFR-mutated non–small cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitors (TKIs) are needed to address EGFR TKI resistance after osimertinib.
Lung cancer diagnosis | Image Credit: Vitalii Vodolazskyi-stock.adobe.com
August 1st 2024

NSCLC Study Highlights Need for Adjuvant Trials in Early-Stage Disease

Maggie L. Shaw
Visceral pleural invasion of non–small cell lung cancer (NSCLC) was investigated in this analysis for its potential to predispose patients to worse survival outcomes and greater chances of disease recurrence.
Jason Porter, MD, an expert on lung cancer
August 1st 2024

ASCO 2024 and Beyond: Addressing NSCLC Unmet Needs and Future Research Directions

Jason Porter, MD
Jason Porter, MD, provides concluding insights on the LAURA phase 3 trial, CHRYSALIS-2 study, TROPION-Lung05 trial, and CheckMate 9LA study, along with other notable findings from the ASCO 2024 conference.
FDA | Image Credit: wladimir1804-stock.adobe.com
July 28th 2024

ODAC Votes to Require Trial Assessment of Neoadjuvant vs Adjuvant Benefits in Resectable NSCLC

Caroline Seymour
Should the FDA require that new trial design proposals for perioperative regimens for resectable non–small cell lung cancer (NSCLC) include adequate within trial assessment?
Lungs | Image credit: yodiyim - stock.adobe.com
July 25th 2024

Atezolizumab for NSCLC Safe and Effective Before and After CRT

Julia Bonavitacola
Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.
Jason Porter, MD, an expert on lung cancer
July 24th 2024

Long-Term Follow-Up from CheckMate 9LA at ASCO 2024

Jason Porter, MD
A key opinion leader examines the overall survival data from the CheckMate 9LA study, which evaluated nivolumab plus ipilimumab plus chemotherapy in metastatic non-small cell lung cancer patients, and explores how the long-term follow-up results inform treatment decisions in this setting.
Jason Porter, MD, an expert on lung cancer
July 24th 2024

Insights from the TROPION-Lung05 Trial at ASCO 2024

Jason Porter, MD
Jason Porter, MD, analyzes the TROPION-Lung05 trial investigating Dato-DXd in non-small cell lung cancer patients with brain metastases, emphasizing crucial insights from this pivotal study.
Antibiotics and lung cancer | Image Credit: Елена Бутусова-stockk.adobe.com
July 19th 2024

NSCLC Care Could Benefit From Antibiotic Stewardship

Maggie L. Shaw
For this analysis, investigators were interested in patient non–small cell lung cancer (NSCLC)–related outcomes from antibiotic administration before immunotherapy alone or immunotherapy and chemotherapy.
Jason Porter, MD, an expert on lung cancer
July 17th 2024

Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024

Jason Porter, MD
A key opinion leader examines the combination therapy of amivantamab and lazertinib in the CHRYSALIS-2 study for treatment-naïve patients or those with 2 or more prior lines of therapy, and its potential implications for non-small cell lung cancer treatment.
Jason Porter, MD, an expert on lung cancer
July 17th 2024

ASCO 2024: Key Findings of the LAURA Trial on Osimertinib for EGFR-Mutated NSCLC

Jason Porter, MD
Jason Porter, MD, analyzes critical insights from the 2024 ASCO Annual Meeting presentation on progression-free survival data from the LAURA phase 3 trial, which evaluated osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer who did not progress after definitive chemoradiotherapy.
Jessica K. Paulus, ScD, Ontada
July 13th 2024

Lung Cancer Detection Trends Show Shift in Pandemic Aftermath

Maggie L. Shaw
In this final segment of our interview with Ontada's Jessica K. Paulus, ScD, she explains how her team's data presented at the American Society of Clinical Oncology annual conference may translate to the real world.
AJMC
July 10th 2024

Patient Satisfaction With Letter-Based Communication of LCS Pulmonary Nodule Results

Daoyue Wang, MD Rui Shi, MD Lili Hu, MD Ran Chen, MD Jun Sun, BS Wei Huang, BS Hongyang Zhou, BS Feng Rong, MD
Patients were satisfied with receiving their lung cancer screening (LCS) pulmonary nodule results via letter and considered the amount of information provided in the letter appropriate.
lung surgery | Image Credit: Tom-stock.adobe.com
July 9th 2024

Age, Pneumonectomy Linked to Poor NSCLC Surgery Outcomes

Maggie L. Shaw
This new analysis incorporated 1997-2013 data on patients with a history of surgical resection of stage IIIA-N2 non-small cell lung cancer (NSCLC) and their postop complications to evaluate the possibility of better identifying future surgical candidates.
<123456>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo